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Immunological consequences of ketogenic diet-induced 
shifts in the gut microbiota 
 
Qi Yan Ang 
Abstract 
 
Very low-carbohydrate, high-fat “ketogenic” diets (KDs) induce a pronounced shift in 
metabolic fuel utilization that elevates circulating ketone bodies; however, the 
downstream consequences of these compounds for host-microbiome interactions 
remains unknown. My thesis work shows that KDs alter the human and mouse gut 
microbiota in a manner distinct from high-fat diets (HFDs). Metagenomic and 
metabolomic analyses of stool samples collected during an 8-week inpatient study 
revealed marked shifts in gut microbial community structure and function during the KD. 
Gradient diet experiments in mice confirmed the unique impact of KDs relative to HFDs 
with a reproducible depletion of Bifidobacteria. In vitro and in vivo experiments showed 
that ketone bodies directly inhibit bifidobacterial growth. Finally, mono-colonizations and 
human microbiome transplantations into germ-free mice revealed that the KD-associated 
gut microbiota reduces the levels of pro-inflammatory Th17 cells in the gut. Together, 
these results highlight the importance of trans-kingdom chemical dialogues for mediating 
the host response to dietary interventions. 
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Chapter 1. 
Introduction 
1.1 The gut microbiome 
 
The trillions of microorganisms within the gastrointestinal tract are collectively termed the 
gut microbiota. Recent studies have highlighted the dynamic and complex crosstalk that 
exists between the host and its microbial communities. We now know that the gut 
microbiota perform many essential functions for the host including nutrient extraction 
(Cani et al. 2019), defense against pathogen colonization (Pickard et al. 2017), and 
modulation of immune function (Rooks and Garrett 2016). Alterations in gut microbiota 
have also been linked to a variety of conditions including metabolic (Koeth et al. 2013; 
Turnbaugh et al. 2006; Thingholm et al. 2019) and inflammatory diseases (Frank et al. 
2007; Scher et al. 2013) and even cognitive dysfunction (Olson et al. 2018; Sharon et al. 
2019), while recent work has also highlighted how microbial drug metabolism can 
influence treatment efficacy (Lam, Alexander, and Turnbaugh 2019). In turn, the gut 
microbiota are influenced by multiple host and environmental factors, with host diet as a 
major factor shaping gut microbial composition and function (Carmody et al. 2015). A 
multitude of studies have explored the impact of macronutrient intake on community 
composition of the gut microbiota, with a high-fat diet (HFD) being the most often-studied 
dietary intervention (Turnbaugh et al. 2008).  
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1.2 Ketogenic diets and the gut microbiome 
 
Very low-carbohydrate, high-fat “ketogenic” diets (KDs) have become increasingly 
popular for weight loss and glycemic control, but the metabolic consequences of such 
diets are incompletely understood (Hall and Chung 2018). Given the emerging evidence 
that the gut microbiota is both highly sensitive to dietary intake (Carmody et al. 2015) and 
plays a central role in coordinating host energy balance (Bäckhed et al. 2004; Turnbaugh 
et al. 2006; Cani et al. 2019), I hypothesized that KDs could act in part by shaping the gut 
microbiota. The premise for this hypothesis is supported by multiple recent studies in 
rodent models demonstrating that the consumption of a KD alters the structure and 
function of the gut microbiota (Olson et al. 2018; Cani et al. 2007). This effect also appears 
to be relevant to the human gut microbiome in states of health and disease. For example, 
the consumption of a nearly carbohydrate-free KD derived entirely of animal products 
reproducibly altered the structure, gene expression, and metabolic activity of the human 
gut microbiome within days (David et al. 2014). Furthermore, the administration of a KD 
to non-alcoholic fatty liver patients altered the human gut microbiome (Mardinoglu et al. 
2018).  
Yet multiple fundamental questions remain unaddressed. The results of past 
human studies have been confounded by other changes in caloric and macronutrient 
intake (David et al. 2014; Mardinoglu et al. 2018) that could have ketogenesis-
independent effects on the gut microbiome. More importantly, the mechanisms through 
which KDs alter gut bacterial abundance are currently unknown, as are the downstream 
consequences of these changes for host metabolic and immunologic phenotypes. 
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In my thesis work, I begin to address these questions through the combined use 
of controlled dietary interventions in overweight and obese individuals and follow-on 
studies in conventional and gnotobiotic mice. I show that the impact of KDs on the gut 
microbiota is distinctive from -- and in some cases the opposite of -- the impact of common 
high-fat, high-sugar “Western” diets. The observed changes in gut microbiota appear to 
be driven not only by dietary macronutrients but also by host production of ketone bodies, 
which inhibit bacterial growth in mice and in vitro mono-cultures. Ketogenesis 
reproducibly decreased the relative abundance of Bifidobacteria in humans and mice, 
which play a causal role in KD-associated decreases in intestinal inflammation. Together, 
these results emphasize the importance of considering the chemical dialogues between 
host and microbial cells to gain a more comprehensive view of the mechanistic links 
between diet and host physiology.  
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Chapter 2.  
Ketogenic diets reproducibly alter the human gut 
microbiome 
To study the impact of severe carbohydrate restriction on the human gut microbiota, I 
turned to fecal samples collected from an inpatient crossover study led by Kevin D. Hall 
(Hall et al. 2016). In this clinical study, 17 adult, overweight or class I obese, non-diabetic 
male participants were first fed a baseline diet for 4 weeks (BD, 50% Carbohydrate, 15% 
Protein, 35% Fat) followed by a 4-week very-low-carbohydrate ketogenic diet (KD, 5% 
Carbohydrate, 15% Protein, 80% Fat)1 (Figure 2.1A) which resulted in significant 
elevations in circulating plasma ketones, a hallmark of ketogenic diets (Figure 2.1B). 
Diets provided were isocaloric during BD and KD periods and matched to each 
participant’s energy expenditure. Five daily stool samples were collected in the final week 
of each diet period. As previously reported, the subjects were in a similar state of  mild 
negative energy balance during the BD and KD fecal collection periods (Hall et al. 2016).  
16S rRNA gene sequencing revealed that the KD resulted in significant 
compositional shifts of the gut microbiome across all individuals (Figure 2.1C) and altered 
the relative abundance of the major bacterial phyla (Figure 2.1D), consistent with a prior 
human study from our lab (David et al. 2014). Nineteen genera were significantly altered 
with Bifidobacterium showing the greatest decrease on KD (Figure 2.1E). Metagenomic 
shotgun sequencing of paired stool samples from the two diet arms confirmed the 
 
1 More details on the daily diet composition as well as sample menus during BD and KD diet stages can be 
found in Hall, Kevin D., Kong Y. Chen, Juen Guo, Yan Y. Lam, Rudolph L. Leibel, Laurel Es Mayer, Marc 
L. Reitman, et al. 2016. “Energy Expenditure and Body Composition Changes after an Isocaloric Ketogenic 
Diet in Overweight and Obese Men.” The American Journal of Clinical Nutrition 104 (2): 324–33. 
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dramatic reduction of several bifidobacterial species on KD across all individuals (Figures 
2.2A and 2.2B). Global profiling of the fecal metabolome by 1H NMR (Figure 2.1F) 
revealed distinct clustering between BD and KD diets despite no significant difference in 
bacterial load (Figure 2.1G) between stool samples from the two diet arms. Overall, these 
results suggest that KD reproducibly alters the human gut microbial community structure 
and function.  
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Figure 2.1. A ketogenic diet alters the human gut microbial community structure 
relative to an isocaloric control diet.  
(A) Daily diet composition during the baseline diet (BD) and ketogenic diet (KD) stages 
respectively, represented in percent calories. (B) Plasma levels of the ketone bodies 
acetoacetate (AcAc) and β-hydroxybutyrate (βHB) significantly increased during KD 
across all 17 study participants (***P < 0.001; paired t-test). (C) Reproducible shifts in gut 
microbial community structure are observed across study participants on the first principle 
coordinate (PCo1) of PhILR Euclidean distances between the two diet stages (P = 0.001, 
r2 = 0.024, ADONIS with Subject ID as stratum), despite significant inter-individual 
variation in community structure between subjects (P = 0.001, r2 = 0.845, ADONIS testing 
for Subject ID). (D) KD alters the relative abundance of the major phyla in the human gut 
microbiota (*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant; paired Wilcoxon test). 
(E) Fold change of genera whose abundances were significantly altered by KD (FDR < 
0.05, DESeq2). (F) OPLS-DA score plot from 1H NMR spectra of fecal metabolite profiles 
between BD and KD diet stages across 17 study participants. The OPLS-DA model was 
validated with a 7-fold cross validation method; R2 value represents predictive power 
(R2>0.5 suggests model is robust) and Q2>0.4 value suggests the model is valid. (G) 
Fecal DNA content is not significantly different between the two diet stages (ns, not 
significant; paired t-test). Data are presented as mean±SEM. 
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Figure 2.2. Metagenomic sequencing reveals decreased abundance of 
bifidobacterial species on the ketogenic diet in our human cohort.  
(A) Heatmap showing fold change of the 50 most abundant species, comparing the 
ketogenic diet (KD) to baseline diet (BD) stages across all 17 subjects in our human study. 
Bacterial species are ordered by the magnitude and direction of the average fold change, 
from the most negative (top) to positive (bottom). (B) The ketogenic diet results in 
consistent reductions in the abundance of bifidobacterial species in our human cohort. 
Each line connects paired samples between the two diet arms from each study subject, 
for bifidobacterial species detected in a study subject’s gut microbiota. 
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Chapter 3.  
Ketogenic diets alter the gut microbiome in a 
manner distinct from high-fat diets 
 
3.1 Short and long-term diet experiments 
 
An apparent paradox is that while studies in mice have repeatedly found that high-fat, 
high-sugar (HFHS) diets increase the Firmicutes at the expense of the Bacteroidetes 
(Carmody et al. 2015; Turnbaugh et al. 2008; Bisanz et al. 2019), my results in humans 
demonstrate that high-fat, very low-carbohydrate KDs have the inverse effect. To address 
this discrepancy, I fed conventionally-raised C57BL/6J adult mice three semi-purified 
diets with identical ingredients but varying in the proportion of calories from fat and 
carbohydrates (Figure 3.1A): low-fat diet (LFD, 78/12/10 carbohydrates/fat/protein); high-
fat diet (HFD, 15/75/10); and KD (0/90/10). As expected, the KD significantly raised 
plasma levels of the ketone body β-hydroxybutyrate (βHB) compared to baseline levels 
in the other diet groups (Figure 3.1B). Due to the relatively high caloric density of HFD 
and KD, mice fed these diets ate more calories on average compared to mice fed chow 
or LFD, with no difference in caloric intake observed between the HFD and KD diet groups 
(Figure 3.1C). There was a significant effect of diet on gut microbial composition (Figure 
3.1D). Consistent with prior work in mice and humans (Carmody et al. 2015; David et al. 
2014), the HFD significantly increased the relative abundance of the Firmicutes phylum 
at the expense of the Bacteroidetes; however, the KD partially reversed this trend (Figure 
3.1E). I also observed that the KD significantly decreased the relative abundance of 
Actinobacteria to a level similar to that of a low-fat, high-plant-polysaccharide chow diet 
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(Figure 3.1E). Comparing HFD and KD, there were ten significantly altered genera 
(Figure 3.1F) with Bifidobacterium showing one of the greatest decreases on KD similar 
to that observed in the human study (Figure 2.1E). To address the possibility that overall 
alterations in microbial abundance could underpin the observed changes in microbial 
compositionality (Vandeputte et al. 2017), I determined total microbial colonization level 
by quantitative PCR (qPCR); there was no significant difference in microbial load among 
the diets (Figure 3.1G). Furthermore, these observed microbial shifts were stable and 
reproducible over 10 weeks of dietary intervention (Figures 3.2A and 3.2B) in animals at 
an independent mouse facility and also with even longer-term feeding of these diets in a 
healthspan and longevity cohort (Newman et al. 2017) where I collected fecal samples 
from mice fed these respective diets over a period of up to 11 months at the time of 
sampling (Figures 3.2C and 3.2D). 
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Figure 3.1. The impact of a ketogenic diet on the gut microbiota is distinct from a 
high-fat diet.  
(A) Macronutrient composition (in percent calories) of the chow diet and three semi-
purified diets: low-fat diet (LFD), high-fat diet (HFD) and ketogenic diet (KD). (B) 
Circulating β-hydroxybutyrate (βHB) levels in mice on diets for 3 weeks (n = 6 mice/group, 
***P < 0.001; one-way ANOVA with Tukey’s test). (C) Average daily calorie intake in mice 
fed the respective diets over three weeks (n = 6 mice/group, *P < 0.05, **P < 0.01, ***P 
< 0.001, ns = not significant; one-way ANOVA with Tukey’s test). (D) Principal coordinate 
analysis of PhILR Euclidean distances reveal significant effect of diet on community 
composition (P = 0.001, r2 = 0.60; ADONIS) and also significant differences in community 
composition comparing HFD to KD (P = 0.005, r2 = 0.45; ADONIS). (E) Relative 
abundance of the major phyla in the microbial communities of mice on respective diets (n 
= 4-6 mice/group, *P < 0.05, **P < 0.01; Kruskal-Wallis with Dunn’s test). (F) Fold change 
from baseline of genera whose abundances were significantly different between HFD and 
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KD (FDR < 0.1, DESeq2), in mice fed KD (n = 6 mice). (G) Fecal bacterial DNA content, 
expressed as 16S rRNA gene copies/ gram wet weight, of mice on respective diets is not 
significantly different (n = 6 mice/group; one-way ANOVA with Tukey’s test). Data are 
presented as mean±SEM. Each data point represents an individual, singly-housed 
animal. 
 
 
 
 
 
Figure 3.2. The ketogenic diet results in stable and reproducible shifts in gut 
microbial composition.  
(A) Principal coordinate analysis of PhILR Euclidean distances reveal distinct clustering 
of KD samples and a significant effect of diet on community composition (P = 0.001, r2= 
0.31, ADONIS) in mice fed the respective diets over 10 weeks. (B) Relative abundance 
of the major phyla in the microbial communities of mice on respective diets, averaged 
from weekly samples. (n = 8 mice/group with mice housed in pairs, *P < 0.05, **P < 0.01, 
***P < 0.001; Kruskal-Wallis with Dunn’s test). (C) Principal coordinate analysis of fecal 
samples collected at a single time point from a healthspan and longevity cohort (Newman 
et al. 2017) reveals a significant effect of diet on community composition (P = 0.001, r2= 
0.33, ADONIS) with long-term feeding of the respective diets (range 28 - 311 days at the 
time of sample collection). Each data point represents an individual animal (n = 21 - 35 
mice/group with 3-5 mice housed per cage). (D) Relative abundance of the major phyla 
in the microbial communities of mice fed the respective diets long-term (n = 21 - 35 
mice/group, *P < 0.05, ***P < 0.01; Kruskal-Wallis with Dunn’s test). Data are presented 
as mean±SEM. 
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3.2 Diet experiments using an alternative carbohydrate source 
 
Next, I sought to determine if the effect of a KD on the gut microbiota would be replicable 
with an alternative carbohydrate source enriched for plant polysaccharides that require 
gut microbial metabolism for their digestion. I designed a parallel set of semi-purified diets 
varying in carbohydrate and fat content and using the same ingredients except replacing 
half of the corn starch by weight with a resistant starch source (high amylose corn starch) 
(Figure 3.3A). I then performed an experiment in which mice were sequentially fed these 
diets in order of decreasing dietary carbohydrate content, switching to a different diet 
every 3 days. Consistent with prior work in mice and humans documenting the rapid effect 
of diet on the gut microbiota (David et al. 2014; Carmody et al. 2015; Turnbaugh et al. 
2009), I observed rapid shifts in the gut microbial communities of mice within a day of 
feeding on each diet (Figure 3.3B). I also observed that the addition of resistant starch 
to the semi-purified diets preserved the relative abundance of Bacteroidetes relative to 
the chow diet and the proportion of Bacteroidetes decreased while Firmicutes increased 
almost linearly with decreasing dietary carbohydrate content (Figure 3.3C) revealing a 
dose-dependent response to diet as previous work suggested (Carmody et al. 2015). In 
contrast to the two major bacterial phyla, Actinobacteria showed a non-linear dose 
response to dietary carbohydrate content which was also detectable at the genus level 
(Bifidobacterium) (Figure 3.3D), a result confirmed with a 3-week dietary intervention 
where mice were split into separate diet groups (Figure 3.3E), and comparable to that 
observed in the original diet experiments I performed using diets without added resistant 
starch (Figure 3.1E). To my knowledge, this is the first example of a non-linear dose 
response between a dietary perturbation and the gut microbiome, suggesting that there 
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may be a “tipping point” at which the host and/or the microbiome responds differently to 
macronutrient intake. 
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Figure 3.3. The effect of a ketogenic diet on the gut microbiota is replicable with an 
alternative carbohydrate source enriched for plant polysaccharides.  
(A) Macronutrient composition (in percent calories) of standard chow and a series of semi-
purified diets containing resistant starch and with varying carbohydrate and fat content: 
low-fat diet (LFD), 45%-fat high-fat diet (HFD45), 75%-fat high-fat diet (HFD75), and 
ketogenic diet (KD). (B) Rapid shifts in gut microbial composition are observed within a 
day of feeding of each diet. Mice were fed each diet for 3 days in a sequential order: Chow 
→ LFD → HFD45 → HFD75 → KD, and dashed vertical lines represent the switch of 
diets. Axis 1 of principal coordinate analysis (PCo1) on PhILR Euclidean distances is 
shown over the 15-day study period (n = 4 mice). (C) Relative abundance of the major 
phyla in the microbial communities of mice fed the respective diets over 15 days reveal 
both linear (Bacteroidetes and Firmicutes) and non-linear (Actinobacteria) dose 
responses to dietary carbohydrate (n = 4 mice). (D) Abundance of Bifidobacterium in the 
murine fecal microbiota over study period, showing decrease on KD to a level similar to 
that of chow diet (n = 4 mice). (E) Relative abundance of the major phyla in the microbial 
communities of mice fed the respective diets over 3 weeks in a separate experiment (n = 
4 mice/group, *P < 0.05; Kruskal-Wallis with Dunn’s test). Data are presented as 
mean±SEM. Each data point represents an individual, singly-housed animal. 
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3.3 Fine dietary gradient experiments 
 
I then sought to more precisely identify the tipping point at which the gut microbiota 
responds differently to changes in the proportions of dietary macronutrients. I designed 
additional diets containing varying carbohydrate (CHO) content that were between the 
original HFD (HFD75; 15% CHO) and KD (0% CHO) (Figure 3.4A): HFD85 (5/85/10 
CHO/fat/protein) and HFD89 (1/89/10). HFD75 (15% CHO) was based on a previous 
study (Newman et al. 2017) which determined the lowest possible dietary carbohydrate 
content that would not increase circulating ketone bodies over background levels. Mice 
fed the diets containing less than 15% carbohydrate (HFD85, HFD89, KD) exhibited 
elevated ketone body levels over baseline levels in mice fed HFD75, with circulating 
ketone body levels increasing as dietary carbohydrate content decreased (Figure 3.4B). 
Despite these relatively modest changes in macronutrient composition, I observed broad 
changes in gut microbial composition at the phylum level, with a significant increase in 
the abundance of Bacteroidetes on all three diets compared to HFD75 and a progressive 
decrease in Actinobacterial abundance with decreasing carbohydrate content (Figure 
3.4C). These results suggest that partial induction of ketogenesis is sufficient to alter the 
gut microbiota despite the continued intake of carbohydrates. 
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Figure 3.4. Modest changes in dietary carbohydrate associated with partial 
ketogenesis is sufficient to alter gut microbial composition. 
(A) Macronutrient composition (in percent calories) of four semi-purified diets in order of 
decreasing carbohydrate content from 15% (HFD75) to 0% (KD). The carbohydrate 
(CHO) and fat content of each diet are shown below the barplots, with protein content 
matched across all diets. (B) Circulating β-hydroxybutyrate (βHB) levels in mice fed diets 
shown in panel G for 3 weeks (n = 5 mice/group, *P < 0.05, **P < 0.01; one-way ANOVA 
with Tukey’s test). (C) Relative abundance of the major phyla in the microbial 
communities of mice on respective diets (*P < 0.05, **P < 0.01; Kruskal-Wallis with Dunn’s 
test). Data are presented as mean±SEM. Each data point represents an individual, singly-
housed animal.  
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Chapter 4.  
Mechanistic links between the ketogenic diet and gut 
microbiome 
4.1 Mucus foraging  
 
I next wanted to explore the potential mechanism(s) that could contribute to the gut 
microbial changes between the HFD and KD. I first considered the contribution of the 
mucus layer, given previous work which demonstrated the promotion of mucus foraging 
activity in the gut bacteria of mice fed polysaccharide-deficient diets (Earle et al. 2015; 
Desai et al. 2016; Sonnenburg et al. 2005). Since carbohydrates in particular dietary fiber 
or complex carbohydrates that reach the distal gut are the principal carbon and energy 
source for colonic microbes, I wondered if the lack of dietary carbohydrates on KD could 
be driving the gut microbial response to KD. Previous reports have shown that low-fiber 
diets promote the expansion and activity of colonic mucus-degrading bacteria which 
utilize host-secreted mucus glycoproteins as an alternative nutrient source, correlating 
with reduced thickness of the mucus layer in gnotobiotic and humanized mouse models 
(Earle et al. 2015; Desai et al. 2016). However, quantification of the overall mucus 
thickness on methacarn-fixed distal colon sections did not reveal thinning of the mucus 
layer on KD (Figures 4.1A, 4.1B), suggesting that KD maintains a robust mucus layer in 
conventional mice despite lack of fermentable carbohydrates. I also did not observe 
changes in the mRNA expression of mucin-2 glycoprotein (MUC2), the main colonic 
mucin isoform, thus ruling out compensatory changes in MUC2 gene expression in the 
host epithelium (Figure 4.1C). Furthermore, MUC2-deficient mice fed KD exhibit changes 
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in the gut microbiota similar to that of wild-type mice (Figure 4.2), suggesting that the 
presence of colonic mucins is not necessary for the observed gut microbial changes on 
KD. Overall, these results suggest that mucus-degrading activity is unlikely to be a 
significant driver of the gut microbial shifts between HFD and KD. 
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Figure 4.1. A ketogenic diet maintains a robust mucus layer despite lack of 
fermentable carbohydrates.  
(A) Representative images of distal colon sections from conventional mice fed chow, low-
fat diet (LFD), high-fat diet (HFD), or ketogenic diet (KD). Sections were stained with DAPI 
(epithelium, blue), UEA1 lectin (mucus, green) and EUB338 universal bacterial FISH 
probe (red). Images were further processed using BacSpace (Earle et al. 2015) and the 
computed luminal debris appears in yellow. (B) Average mucus widths in distal colons of 
conventional mice fed the respective diets after 3 weeks, quantified using BacSpace 
(Earle et al. 2015) (n = 3 - 5 mice/group, ns = not significant; one-way ANOVA). (C) 
Quantitative PCR of colonic Muc2 transcripts reveal no significant difference in Muc2 
relative gene expression (n = 3 - 5 mice/group, ns = not significant; one-way ANOVA). 
Data are presented as mean±SEM. Each data point represents an individual, singly-
housed animal. 
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Figure 4.2. Gut microbial shift on a ketogenic diet is independent of colonic mucin.  
(A) Representative images of distal colon sections from wild-type (WT) and Muc2-/- mice 
respectively, showing lack of goblet cells and mucus layer in Muc2-/- mice with bacteria in 
close contact with gut epithelium. Sections were stained with DAPI (epithelium, blue), 
UEA1 lectin (mucus, green) and EUB338 universal bacterial FISH probe (red). (B) 
Principal coordinate analysis of PhILR Euclidean distances reveal significant clustering 
of microbial communities in WT and Muc2-/- littermates by diet (P = 0.001, r2= 0.41, 
ADONIS) but not genotype (P = 0.076, r2= 0.096, ADONIS); n = 3-4 mice per genotype-
diet group. (C) Fold difference of genera whose abundances are significantly different 
between HFD and KD (FDR < 0.1, DESeq2), in WT and Muc2-/-  mice respectively (n = 3-
4 mice per genotype-diet group). 
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4.2 Bile acids 
 
I next considered bile acids as another potential mechanism due to their role in fat 
emulsification; however, there was no significant difference in the overall bile acid pool in 
the human fecal samples comparing BD to KD (Figure 4.3A) nor in mouse cecal contents 
collected on the HFD or KD (Figure 4.3B). Five bile acid species were found to be 
significantly different between the two diet arms in the human study: decreased levels of 
ursocholanic acid and lithocholic acid, and increased levels of deoxycholic acid, β-
muricholic acid and taurolithocholic acid on the KD relative to BD. However, none of these 
changes were recapitulated in the mouse model thus ruling out differences in bile acids 
as a common factor driving the gut microbial changes observed on the ketogenic diet in 
mice and humans. 
 
 
 
Figure 4.3. Overall bile acid pool is not significantly altered by a ketogenic diet in 
humans and mice.  
(A, B) Concentration of total, free, and conjugated bile acids (BA) is not significantly 
different in (A) fecal samples from study participants during the baseline diet (BD) and 
ketogenic (KD) diet stages, nor (B) cecal contents from mice fed a high-fat diet (HFD) or 
ketogenic diet (KD). Data points represent paired stool samples from study participants 
during the two diet arms (A) or individual mice (B). Statistical analyses were performed 
using paired (A) or unpaired (B) t tests. 
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4.3 Ketone bodies 
 
A far less well-characterized factor that could in theory impact gut bacterial growth is the 
ketone bodies that are significantly elevated on the KD compared to the HFD in human 
and mouse studies (Figure 2.1B, 3.1B, and 3.4B), which are indicative of increased lipid 
oxidation in response to severe carbohydrate restriction. Interestingly, while the liver is 
the primary ketogenic organ in mammals, gut epithelial cells are also capable of 
producing ketone bodies (Puchalska and Crawford 2017), and previous work has shown 
increased local concentrations of βHB in the intestines with KD feeding (Tognini et al. 
2017). This prompted me to wonder if production of ketone bodies by the gut epithelium 
during KD might impact the gut microbiome.  
To investigate the impact of ketone bodies on the gut microbiome in the absence 
of carbohydrate restriction, I supplemented the HFD and KD with a synthetic ketone ester 
(KE) compound (Figure 4.4A) that is readily hydrolyzed in the intestinal lumen to produce 
β-hydroxybutyrate (βHB), thus mimicking intestinal production of ketone bodies. Given 
the nature of βHB as an organic acid that is rapidly catabolized, the use of this ketone 
ester as a prodrug avoids the problem of excessive acid or salt load with exogenous 
delivery βHB while sustaining βHB levels over a long period (Newman and Verdin 2017). 
The ketone ester consists of three constituent groups linked by ester bonds: the ketone 
body βHB, hexanoic acid (6-carbon fatty acid), and hexanol (6-carbon alcohol); the ester 
bonds are readily cleaved by esterases ubiquitous in the gut releasing free βHB as well 
as hexanol and hexanoic acid which are transported to the liver where they are further 
metabolized to βHB. In two independent experiments, I showed that supplementation of 
the ketone ester to a HFD (HFD-KE diet) significantly raised circulating levels of βHB over 
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baseline on the HFD, albeit at comparative smaller magnitude than KD consumption over 
3 weeks (Figure 4.4B). More importantly, I also showed that dietary KE supplementation 
increased βHB levels in the intestinal lumen (Figure 4.4C), providing evidence that the 
KE compound could successfully reach the intestinal lumen and is hydrolyzed locally to 
release βHB, thus allowing me to investigate how the ketone body could potentially 
interact with gut bacteria. To my knowledge, there is currently no published data 
demonstrating the local regulation of βHB in the gut with dietary supplementation of 
ketone esters in rodent models nor humans, which highlights the practical implications of 
this work given the growing interest in the use of exogenous ketone bodies as potential 
therapeutic tools (Murray et al. 2016; Stubbs et al. 2017; Veech et al. 2017; Clarke et al. 
2012). 
I profiled the gut microbial communities of mice fed the respective diets via 16S 
rRNA gene sequencing, revealing that KE supplementation significantly altered gut 
microbial composition (Figure 4.4D). Next, I sought to identify bacterial taxa that were 
specifically altered by the presence of βHB and would therefore exhibit changes in 
abundance with a similar pattern to the expected levels of βHB in the gut lumen. I 
searched for genera that were consistently altered in comparisons between the HFD and 
KD in addition to KE supplementation, revealing three genera that overlapped in 
directionality of fold change which were Bifidobacterium, Lactobacillus, and Acetatifactor 
(Figure 4.4E). In particular, Bifidobacterium exhibited changes in abundances that were 
commensurate with βHB levels in mice fed HFD, KD or ketone-supplemented diets 
(Figure 4.4E), consistent with my observations that Bifidobacterium showed decreased 
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abundance on the KD in both humans and mice (Figure 2.1E and 3.1F), suggesting that 
βHB can directly impact Bifidobacterium growth in vivo. 
 
 
 
Figure 4.4. Ketone bodies alter gut microbial composition. 
(A) Chemical structure of the ketone ester (KE) comprising β-hydroxybutyrate (βHB) 
linked to two 6-carbon medium chain fatty acids which are metabolized to βHB. (B) 
Circulating βHB levels in mice fed HFD, KE-supplemented HFD (HFD-KE), KD, or KE-
supplemented KD (KD-KE) respectively for 3 weeks (n = 11-12 mice/group from two 
independent experiments, **P < 0.01, ***P < 0.001; Welch’s t-test comparing HFD to each 
of the other diets). (C) βHB concentration in cecal contents of mice fed HFD, KE-
supplemented HFD (HFD-KE), KD, or KE-supplemented KD (KD-KE) respectively for 3 
weeks (n = 11-12 mice/group from two independent experiments, *P < 0.05, **P < 0.01; 
one-way ANOVA with Tukey’s test). (D) Principal coordinates analysis of PhILR 
Euclidean distances reveal distinct clustering of microbial communities between diet 
groups (P = 0.001, r2 = 0.41, ADONIS), and microbial communities on the HFD diet are 
significantly different from each of the other diet groups (P and r2 values are indicated on 
the PCoA plot, ADONIS). (E) Fold change of genera that are consistently altered in 
comparisons between HFD vs. KD and HFD vs. HFD-KE (FDR < 0.2, linear mixed effects 
model with MouseID as random effect), compared to baseline in the microbial 
communities of mice fed the respective diets (n = 4-5 mice/group).  
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Besides microbiota composition, I also monitored effects of the ketogenic diet and 
ketone ester (KE) supplementation on host physiology, namely food consumption and 
body composition. While the KE compound is well-suited for oral feeding, one caveat is 
that esters tend to have strong odors, and my preliminary studies suggest that it takes 
about one week for adult mice to adapt to the KE-supplemented diets, whereas mice 
adapt immediately to the ketogenic diet. Indeed, this was reflected in the first experiment 
I conducted using the KE-supplemented diets, where I observed that adult mice (aged 10 
weeks at the start of the experiment) that were fed the KE-supplemented diets (HFD-KE 
and KD-KE) consumed significantly less calories compared to mice fed HFD or KD in the 
first week of feeding (Figure 4.5A). The mice fully adapted to the diets after the first week, 
with no differences in calorie intake across the four diet groups observed in the second 
and final week of the experiment (Figure 4.5A). In the second experiment where I started 
mice on diets at a younger age (5 weeks at the start of the experiment), there was no 
significant difference in calorie intake throughout the experimental course (Figure 4.5C). 
This discrepancy in the first-week food consumption between the two experiments could 
suggest that the mice adapt more quickly to the odor of the KE at a younger age, though 
I have not specifically tested this hypothesis. More importantly, these observations 
suggest that the gut microbial differences observed with KE supplementation at 
experimental endpoint (Figure 4.4D and 4.4E) were not confounded by differences in 
caloric intake, a potential factor that influences microbiota composition (Jumpertz et al. 
2011).  
 There was no significant difference in the body weights of mice fed HFD versus 
KD over three weeks; both diet groups gained weight steadily over the experimental 
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course (Figure 4.5B and 4.5D). This observation that a normal-protein HFD and KD are 
obesogenic when fed continuously is consistent with prior reports (Newman et al. 2017; 
Borghjid and Feinman 2012). Although there were reports of mouse models of ketogenic 
diet that induced weight loss, these were later found to be attributed to extreme protein 
and/or vitamin deficiency in the diet design (Pissios et al. 2013; Schugar et al. 2013; 
Borghjid and Feinman 2012). It remains an open question as to why rodent models of 
ketogenic diets fail to recapitulate the weight loss effects observed in humans (Mansoor 
et al. 2016; Bueno et al. 2013); it is possible that ketogenic diets induce distinct metabolic 
responses between mice and humans. Given that the gut microbiome is a key regulator 
of host metabolism (Cani et al. 2019), differences in the bacterial species and strain-level 
metabolic capacities found in the gut microbiota of mice versus humans may also 
contribute to the divergent metabolic responses to KD. 
Mice fed the KE-supplemented diets (HFD-KE and KD-KE) gained significantly 
less weight compared to mice fed HFD or KD (Figure 4.5B and 4.5D). This could be 
accounted for by the lower food consumption in mice fed the KE-supplemented diets in 
the first week of diet (Figure 4.5A), yet there was no overall differences in food 
consumption in the second experiment that could explain the lower body weight trajectory 
(Figure 4.5C) in mice fed HFD-KE compared to HFD. In fact, mice fed the HFD-KE diet 
gained significantly less adiposity compared to HFD-fed mice after three weeks (Figure 
4.5E), despite no significant differences in overall calorie intake throughout the dietary 
intervention (Figure 4.5F). For future investigations, it would be interesting to study the 
effect of KE supplementation on energy expenditure, nutrient absorption or other factors 
that could mediate the observed differences in body weight and adiposity. 
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Figure 4.5. Effects of ketone ester feeding on host physiology. 
(A) Daily calorie intake averaged per week in mice fed HFD, KE-supplemented HFD 
(HFD-KE), KD, or KE-supplemented KD (KD-KE) respectively for three weeks (n = 7 
mice/group, *P < 0.05; one-way ANOVA with Tukey’s test). (B) Body weight curves of 
mice fed the respective diets over three weeks (n = 7 mice/group, # and + symbols denote 
significant difference from HFD-KE and KD-KE respectively with significance determined 
as P < 0.05; two-way ANOVA comparing between diets over time). (C) Daily calorie intake 
was not significantly different between diet groups across all three weeks of dietary 
intervention (n = 4-5 mice/group; one-way ANOVA with Tukey’s test). (D) Body weight 
curves of mice fed the respective diets over three weeks (n = 4-5 mice/group, # and + 
symbols denote significant difference from HFD-KE and KD-KE respectively with 
significance determined as P < 0.05; two-way ANOVA comparing between diets over 
time). (E) Change in adiposity determined using EchoMRI at the start and end of dietary 
intervention (n = 4-5 mice/group, *P < 0.05; unpaired t tests). (F) Total calorie intake over 
three weeks of dietary intervention (n = 4-5 mice/group, ns = not significant; unpaired t 
tests). 
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I next investigated whether βHB can directly impact bacterial growth in vitro, by 
comparing anaerobic growth with and without exogenous βHB across a panel of 35 gut 
bacterial isolates from 6 phyla (Figure 4.6A), including bifidobacterial strains isolated 
from stool samples collected in our human study: two strains of Bifidobacterium 
adolescentis (strain BD1 and BD2) — the most abundant and prevalent species of 
Bifidobacterium in our human cohort (Figure 2.2B) — as well as Bifidobacterium longum 
(strain BD3) and Bifidobacterium angulatum (strain BD4). Each isolate was incubated with 
three different concentrations of βHB ranging from 12.5 - 50 µM and bacterial growth in rich 
media was quantified by optical density. For the majority of isolates, the concentration 
required to prevent ≥90% growth (MIC90) occurred between 25 mM to 50 mM, with the 
exception of isolates in the genera Eggerthella and Lactobacillus that were insensitive to 
growth inhibition by βHB at the highest concentration tested (50 mM). On average, the 
Bacteroidetes tended to be sensitive to growth inhibition by βHB relative to the other phyla 
(Figure 4.6B). It is worth noting that βHB concentrations used to achieve MIC90 in these 
bacterial monocultures exceed the physiological range — circulating βHB levels in 
humans rise up to 8 mM with prolonged starvation (Newman and Verdin 2017) — which 
suggests in vitro incubations of bacterial monocultures with βHB may not reflect the 
microenvironment or dynamics of complex communities found in the gut. Nevertheless, 
the ketogenic diet has been shown to increase levels of βHB in the intestinal tissue to the 
millimolar range (Tognini et al. 2017), which could suggest that bacteria residing close to 
the intestinal epithelium may be exposed to relatively high local concentrations of βHB 
similar to the concentrations tested in my in vitro assays. 
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Contrary to the selective reduction of Bifidobacterium and Lactobacillus observed 
in vivo with oral feeding of the ketone ester (Figure 4.4E), I did not observe selective 
inhibition of either genera in the growth curve analyses. This suggests that the selective 
reduction of these genera observed in vivo could be a result of inter-species competition 
rather that direct inhibitory effects; for example, βHB may act as a signaling molecule 
(Newman and Verdin 2017) that alters the gene expression of microbial species in a way 
that causes Bifidobacterium and Lactobacillus to be outcompeted in the context of 
complex communities. Interestingly, I observed that βHB promoted the growth of a few 
bacterial isolates, for example the carrying capacity of Eggerthella sinensis and 
Bifidobacterium animalis were significantly increased in a dose-dependent manner by 
βHB (Figure 4.6C), which raises the intriguing possibility that some gut bacterial species 
could use βHB as a carbon source. In fact, although several genera of bacteria found in 
soil and other environments are known to synthesize and utilize a polymerized form of 
βHB known as poly-β-hydroxybutyrate (Braunegg, Lefebvre, and Genser 1998; S. Y. Lee 
1996), this trait has not yet been characterized in gut bacteria. For future investigations, 
it would be interesting to further explore the mechanism-of-action of βHB on the 
physiology of gut bacteria, and to identify the genes that mediate either the inhibition or 
promotion of bacterial growth by βHB among gut bacterial strains. 
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Figure 4.6. Strain variability in growth responses to βHB in vitro. 
(A) A diverse panel of 35 gut bacterial isolates were incubated with varying concentrations 
of βHB, and a maximum likelihood phylogenetic tree using 16S rRNA gene sequences 
was constructed. Heatmap shows fold change of carrying capacity relative to media 
control at the respective βHB concentrations. F, Fusobacteria; V, Verrucomicrobia. (B) 
The minimum inhibitory concentration required to prevent ≥90% growth (MIC90) of 
bacterial isolates spanning four major phyla. Bacteroidetes tended to be sensitive relative 
to the other phyla when tested in vitro (*P < 0.05; Kruskal-Wallis with Dunn’s test). 
Mean±SEM shown. (C) Representative growth curves of selected isolates grown under 
anaerobic conditions with different concentrations of βHB. Growth curves show 
mean±SEM of triplicate cultures, with optical density (600 nM) measured at 15 min 
intervals over 24 hours.  
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Chapter 5.  
Downstream consequences on host immunity 
5.1 Mono-colonizations  
 
A recent report showed that several Bifidobacterium species from the human gut 
microbiota, in particular B. adolescentis, are sufficient to robustly induce pro-inflammatory 
intestinal Th17 cells in mono-colonized mice (Tan et al. 2016). Given that I have showed 
a reproducible depletion of Bifidobacterium in both humans and mice fed KD as well as 
mice fed a ketone ester-supplemented HFD, I next asked if this could result in differences 
in intestinal Th17 cell accumulation in my studies. I mono-colonized germ-free mice with 
B. adolescentis BD1 (isolated from our human cohort) which resulted in a significant 
increase in Th17 cells in the small (but not large) intestines of mice (Figure 5.1A) that 
were fed a HFD over the course of the experiment, consistent with the published report 
(Tan et al. 2016). Consumption of a KD prevented the induction of intestinal Th17 cells in 
mice mono-colonized with B. adolescentis (Figure 5.1B), consistent with a significant 
decrease in B. adolescentis colonization in the ileum compared to HFD-fed mice (Figure 
5.1C). In contrast, Th1 cell levels were unaffected by KD consumption nor B. adolescentis 
mono-colonization (Figure 5.1D); the latter is consistent with the previous report showing 
preferential induction of Th17 cells in the small intestine by B. adolescentis (Tan et al. 
2016). Taken together, these data suggest that host production of ketone bodies on a KD 
(Figure 5.1E) likely mediates the lack of intestinal Th17 induction in these mice by 
reducing colonization levels of B. adolescentis, and exemplifies the impact of diet-
microbiota interactions on host immunity. 
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Figure 5.1. The ketogenic diet prevents intestinal Th17 induction by 
Bifidobacterium adolescentis in mono-colonized mice. 
(A) B. adolescentis BD1 (BA) induces a robust Th17 population in the small intestine (SI) 
but not large intestine (colon) of mice fed HFD. Th17 populations are measured as IL-
17a+ CD4+ live cell percentages. Black and grey bars represent germ-free (GF) and BA-
monocolonized mice respectively (n = 4 mice/group, *P < 0.05, ns = not significant; 
Welch’s t-test). Representative flow cytometry plots of the IL-17a+ CD4+ live cell 
populations are shown to the left. (B) BA-monocolonized mice fed KD do not show 
intestinal Th17 cell induction compared to germ-free controls fed KD, in the small intestine 
and colon (n = 4 mice/group, ns = not significant; Welch’s t-test). Representative flow 
cytometry plots of the IL-17a+ CD4+ live cell populations are shown to the left. (C) 
Bacterial DNA content, expressed as 16s rRNA gene copies/ gram wet weight in the ileal 
contents from BA-monocolonized mice fed HFD and KD respectively (n = 3-4 mice/group, 
*P < 0.05; Welch’s t-test). (D) Frequencies of Th1 cells in the small intestines are not 
significantly differently between GF and BA-monocolonized mice fed KD compared to 
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HFD. Black and grey bars represent HFD and KD respectively (n = 3-4 mice/group, ns = 
not significant; Welch’s t-test). (E) Circulating βHB levels are significantly elevated in both 
GF and BA-monocolonized mice fed KD compared to HFD (n = 4 mice/group, ***P < 
0.001; Welch’s t-test). Data are presented as mean±SEM. Each data point represents an 
individual, singly-housed animal. 
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5.2 Human microbiota transplantations 
I next wanted to investigate if changes in Bifidobacterium relative abundance in the 
context of an intact human gut microbiota would translate to differences in intestinal Th17 
cell accumulation. I inoculated germ-free mice with fecal microbiota from human donors 
collected during the baseline diet (BD) or ketogenic diet (KD) stages respectively, and 
added a third experimental group in which I supplemented the KD-associated microbiota 
(itself containing a low relative abundance of Bifidobacterium) with B. adolescentis BD1 
(KD+BA), thus recapitulating Bifidobacterium abundance in the BD microbiota at both 
phylum (Figure 5.2A) and genus level (Figure 5.2B) (CLR abundance of Bifidobacterium 
in donor community of BD: 8.14, KD: -2.56, KD+BA: 9.09). 16S rRNA gene sequencing 
of fecal samples showed that distinct microbial communities were established between 
BD and both KD microbiota groups (KD and KD+BA) which clustered similarly on the 
principal coordinates plot (Figure 5.2C). As expected, Bifidobacterium abundance was 
significantly lower in the KD group compared with either BD or KD+BA groups throughout 
the course of the experiment (Figure 5.2D). Consistent with the observed differences in 
Bifidobacterium abundance, mice that received the KD microbiota showed significantly 
lower intestinal Th17 frequency (Figure 5.2E) compared to either BD or KD+BA groups. 
In contrast, there were no significant differences in the Th1 cell population (Figure 5.2F). 
These results demonstrate that changes in the abundance of Bifidobacterium even in 
complex human gut microbial communities can have a meaningful impact on intestinal 
Th17 accumulation. 
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Figure 5.2. The KD-associated human microbiota reduces intestinal Th17 cell 
accumulation.  
Community composition at (A) phylum and (B) genus level of donor fecal samples used 
for gnotobiotic transplant, pooled from the same four individuals during the baseline diet 
(BD) and ketogenic diet (KD) stages respectively, and a third sample comprising the KD 
donor sample supplemented with B. adolescentis BD1 (KD+BA). (C) Fecal microbiota of 
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mice colonized with the donor samples shown in panel A and B, sampled every two days 
post-transplant with sacrifice occurring 12 days post colonization (n = 5-6 mice/group). 
(D) Abundance of B. adolescentis (BA) in the fecal microbiota of mice in the three 
transplant groups, sampled over the course of the experiment (n = 5-6 mice/group). BA 
abundance is significantly different between transplant groups (Pgroup = 1.8e-5; PKD+BAv.KD 
< 0.001; PKD+BAv.BD < 0.01; PBDv.KD = 0.053). Statistical analysis carried out using linear 
mixed effects models (LMM) with MouseID as random effect and Tukey’s test. (E) Mice 
that received the KD microbiota showed significantly lower levels of intestinal Th17 cells 
than either BD or KD+BA transplant groups. Representative flow cytometry plots of the 
IL-17a+ CD4+ live cell populations are shown to the left (n = 4-6 mice/group, **P < 0.01, 
ns = not significant; one-way ANOVA with Tukey’s test). (F) Th1 cell populations in the 
small intestine are not significantly different between transplant groups. Representative 
flow cytometry plots of the IFNγ+ CD4+ live cell populations are shown to the left (n = 4-
6 mice/group, ns = not significant; one-way ANOVA with Tukey’s test). Data are presented 
as mean±SEM. Each data point represents an individual, singly-housed animal. 
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5.3 Conventional mice 
Given that human fecal transplantation of BD vs KD-associated microbiota was sufficient 
to reveal differential accumulation of Th17 cells in the gut, I hypothesized that differences 
in intestinal Th17 frequency should also be detectable in my diet experiments with 
conventional mice. Consistent with this hypothesis, conventional mice fed KD exhibited 
lower levels of Th17 cells in the small intestine (SI) compared to mice fed HFD (Figures 
5.3A and 5.3D). Similarly, mice fed the KE-supplemented HFD, which reduced 
Bifidobacterium abundance in the gut microbiota relative to HFD (Figure 4.4E), led to 
lower Th17 cell accumulation in the small intestines (Figure 5.3A). There were no 
differences in Th17 cell levels in the large intestines (Figure 5.3B) and spleen (Figure 
5.3C).   
I also observed differences in SI Th17 cell accumulation with small changes in 
dietary carbohydrate intake (Figure 3.4A), specifically, there was a significant drop in 
Th17 frequency in mice fed KD compared to those fed similar high-fat, low-carbohydrate 
diets (Figure 5.3D) that is consistent with a significant decrease in Bifidobacterium 
abundance (Figure 5.3E). There was no significant changes in other immune cell subsets 
including Th1 (Figure 5.3F) and Treg (Figure 5.3G) cell populations, suggesting that the 
observed immune changes are specific to Th17 cells. 
Given increasing evidence for immunological crosstalk between the gut and other 
tissue compartments (Y. S. Lee, Wollam, and Olefsky 2018; Winer et al. 2016; Powell, 
Walker, and Talley 2017; Morton et al. 2014), I wondered if the observed differences in 
Th17 responses in the gut could be detected more systemically. Although there was no 
difference in Th17 frequency in the spleen (Figures 5.3C and 5.3H), there was a 
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significant drop in Th17 cell accumulation in visceral adipose tissue on both HFD89 (1% 
CHO) diet and KD compared to the other diets (Figure 5.3I),. This provides initial 
evidence for a gut-adipose Th17 axis and is consistent with prior data suggesting that gut 
microbial-induced changes in the intestinal immune environment could in turn influence 
metabolic tissue inflammation (Winer et al. 2016; Y. S. Lee, Wollam, and Olefsky 2018). 
However, additional studies are warranted to control for circulating βHB which may 
directly decrease Th17 cells in adipose tissue (Puchalska and Crawford 2017). 
Regardless, these observations highlight how very-low-carbohydrate diets (0-1% CHO) 
are distinctive from low-carbohydrate diets (5-15% CHO) in both gut microbial and 
immune responses.  
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Figure 5.3. The ketogenic diet and ketone ester feeding reduces intestinal Th17 cell 
accumulation.  
(A) Conventional mice fed either KD or ketone ester (KE)-supplemented diets show lower 
frequencies of small intestinal Th17 cells compared to mice fed HFD for 3 weeks (n = 4-
5 mice/group, *P < 0.05; one-way ANOVA with Tukey’s test). Representative flow 
cytometry plots of the IL-17a+ CD4+ live cell populations are shown to the left. Th17 cell 
levels were not significantly different in the (B) large intestine and  (C) spleen (ns = not 
significant; one-way ANOVA with Tukey’s test). (D) Conventional mice fed KD show 
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significantly lower Th17 cell accumulation compared to mice fed similar high-fat, low-
carbohydrate diets shown in Figure 3.4A for 3 weeks (n = 4-5 mice/group, *P < 0.05, **P 
< 0.01, ****P < 0.0001; one-way ANOVA with Tukey’s test). Representative flow 
cytometry plots of the IL-17a+ CD4+ live cell populations are shown to the left. (E) 
Bifidobacterium genus abundance in mice fed the respective diets (n = 4-5 mice/group, 
*P < 0.05; Kruskal-Wallis with Dunn’s test). (F) IFNγ+ CD4+ Th1 and (G) Foxp3+ CD4+ 
Treg cell populations in the small intestines were not significantly different between 
groups (ns = not significant; one-way ANOVA with Tukey’s test). (H) No difference in Th17 
cell accumulation in the spleen (ns = not significant; one-way ANOVA with Tukey’s test). 
(I) Frequencies of Th17 cells in the epididymal white adipose tissue of mice fed the 
respective diets for 3 weeks (n = 4-5 mice/group, ***P < 0.001, ****P < 0.0001; one-way 
ANOVA with Tukey’s test). Representative flow cytometry plots of the IL-17a+ CD4+ live 
cell populations in epididymal fat are shown to the left. Data are presented as mean±SEM. 
Each data point represents an individual, singly-housed animal. 
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Chapter 6.  
Conclusions and future directions 
In conclusion, my thesis work demonstrates how diet-induced changes in host-derived 
metabolites can alter the gut microbiota with downstream consequences for host immune 
responses. Through the combined use of controlled dietary interventions in humans and 
follow-on studies in conventional and gnotobiotic mice, I show that the impact of ketogenic 
diets on the gut microbiota are distinctive from that of high-fat diets. These changes 
appear to be driven not only by macronutrient intake but also by the concomitant host 
production of ketone bodies. Inhibition of bifidobacterial growth by ketone bodies results 
in KD-associated decreases in Th17 inflammation in the gut and adipose tissues in mice. 
Given the existing literature linking obesity with chronic low-grade inflammation in 
metabolic tissues (Hotamisligil 2017), decreased levels of pro-inflammatory Th17 cells in 
both gut and adipose tissues on a KD may be a potential mechanism contributing to the 
greater efficacy of KD in improving some aspects of metabolic syndrome such as 
glycemic control (Sainsbury et al. 2018; Saslow et al. 2017) and reductions in body fat 
(Mardinoglu et al. 2018; Volek et al. 2009). Furthermore, while previous work has 
demonstrated gut barrier disruption with consumption of HFHS diets which is associated 
with metabolic endotoxemia and inflammation (Everard et al. 2013), I found that KD 
maintained a robust mucus layer in mice despite the lack of fermentable carbohydrates, 
providing evidence that intestinal homeostasis is preserved on a KD.  
The effects of long-term KD consumption on human health remain unclear, due to 
a lack of long-term studies tracking outcomes in humans adhering to a KD regimen. In 
mice, recent studies have shown long-term KD feeding to enhance longevity and reduce 
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disease onset in adult mice (Roberts et al. 2017; Newman et al. 2017). Aside from 
reported metabolic effects in short-term clinical trials in humans, KDs have been used as 
dietary treatment for intractable epilepsy since the 1920s and recent studies have found 
significantly positive outcomes with the use of KDs for treatment of refractory epilepsy in 
children and adults (Liu et al. 2018; Neal et al. 2008; Kverneland et al. 2015) where anti-
epileptic drugs have failed. However, the mechanisms mediating the efficacy of KD as a 
treatment for epilepsy remain unknown. A recent paper provided intriguing evidence for 
the role of the gut microbiota in mediating anti-seizure effects of KD in mouse models of 
refractory epilepsy (Olson et al. 2018). Interestingly, another recent paper showed 
increased proportion of circulating Th17 cells in patients with intractable epilepsy 
compared to control individuals that was partially reversed following KD consumption (Ni 
et al. 2016), highlighting the potential role of Th17 immune responses in the pathogenesis 
of epilepsy, and consistent with my data showing decreased Th17 cell frequency in both 
the gut and adipose tissues with KD consumption. These observations together provide 
the premise for future investigations into the potential role of Th17 immune responses as 
a mechanism underlying the efficacy of KDs as treatment for refractory epilepsy and 
potentially other diseases associated with increased Th17 activation such as autoimmune 
diseases. More research is required to better understand the long-term consequences of 
KDs in humans in both health and disease. 
 This study highlights the role of the gut microbiota in mediating changes in 
intestinal Th17 cell responses to KD consumption, specifically I focused on 
Bifidobacterium which decreases in abundance during KD consumption in both humans 
and mice and also with feeding of a synthetic ketone ester in mice. I show that these 
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changes in Bifidobacterium abundances in the context of complex communities result in 
a significant alteration to intestinal Th17 cell populations, highlighting the role of 
Bifidobacterium in modulating adaptive immune responses. Importantly, the impact of diet 
and the gut microbiota on Th17 cells may be beneficial or detrimental depending on the 
context, warranting comparative analyses of these complex interactions in the context of 
inflammatory diseases (Tan et al. 2016), defense against enteric pathogens (Honda and 
Littman 2016), and cancer immunotherapy (Matson et al. 2018), among others. Further 
investigation is also needed to explore the potential consequences of changes in other 
members of the gut microbiota observed with KD consumption in our human cohort. Of 
note, both Fusobacteria and Escherichia were significantly enriched on the KD, which 
have both been implicated in predisposition to colorectal cancer (Kostic et al. 2013; 
Dalmasso et al. 2014). These results suggest that the short- and long-term impact of KDs 
on host health and disease likely depends upon a much more complex series of 
beneficial, neutral, and detrimental shifts in microbial ecology which remain to be 
explored.  
 It is worth noting that β-hydroxybutyrate (βHB) itself has anti-inflammatory effects 
due to its ability to inhibit the NLRP3 inflammasome (Puchalska and Crawford 2017). 
Thus, production of βHB during a KD could directly impact immune responses in addition 
to altering microbial mediated immunomodulation. Nevertheless, my thesis work provides 
evidence for a causal contribution of the gut microbiota in mediating the immune 
responses observed with KD consumption, as the transplantation of fecal microbiota from 
human donors fed KD versus a baseline diet into germ-free mice was sufficient to reveal 
differences in intestinal Th17 cell accumulation. My data supports the contribution of 
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select gut bacterial changes, specifically Bifidobacterium, in modulating the intestinal 
Th17 cell population, consistent with previous work which showed that Bifidobacterium 
robustly induced intestinal Th17 cells (Tan et al. 2016). 
 Although my investigations show that the gut microbial changes observed with KD 
consumption are mediated at least in part through host production of ketone bodies, future 
investigation is warranted to dissect the relative contribution of hepatic versus intestinal 
ketogenesis to the observed gut microbial changes. While local production of ketone 
bodies in the gut epithelium is likely to be more relevant to the gut microbiome and there 
is increased expression of ketogenic genes in the intestinal epithelium along with 
increased local concentrations of βHB with KD feeding (Tognini et al. 2017), it is possible 
that elevations of circulating βHB from hepatic production during KD could also directly 
or indirectly shape the gut microbiota. Elucidating the relative impact of intestinal versus 
hepatic ketogenesis on the gut microbiome might provide some insights into the 
physiological roles of ketone body production in the gut epithelium. 
Overall, my thesis work extends important previous findings from our laboratory 
(David et al. 2014; Carmody et al. 2015) and others (Tan et al. 2016), providing evidence 
that the impact of diet on the gut microbiota is not only translatable from animal models 
to humans, but also appears to play a causal role in mediating host phenotypic responses 
to diet. Continued progress in elucidating the mechanistic basis for these observations 
could help inform more personalized approaches to utilize dietary interventions for the 
prevention and treatment of human disease.  
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 Materials and methods 
 
Diets 
All diets were provided ad libitum unless otherwise noted. Semi-purified diets were 
purchased from Envigo. Diet codes and macronutrient compositions of the semi-purified 
diets used are listed in the table below. Standard chow diet (Lab Diet 5058) is used in the 
SPF facility, while standard autoclaved chow diet (Lab Diet 5021) is used in the 
gnotobiotic facility. All diets used for gnotobiotic experiments were either autoclaved or 
irradiated to ensure sterility. 
Table S1. Macronutrient compositions of semi-purified diets used in this study 
Diet Diet Code 
Macronutrient content (% kcal) 
Protein Carbohydrate Fat 
LFD TD.150345 9.7 77.7 12.6 
HFD75 (HFD) TD.160239.PWD 9.8 15.0 75.2 
HFD85 TD.180528.PWD 9.5 5.4 85.1 
HFD89 TD.180527.PWD 9.5 1.4 89.1 
KD TD.160153.PWD 9.5 0.0 90.5 
HFD-KE TD.170411 10.0 15.2 71.3 
KD-KE TD.170412 9.6 0.0 87.4 
LFD *RS TD.160494 
 
10.3 76.4 13.3 
HFD45 *RS TD.160495 
 
10.2 43.3 46.6 
HFD75 *RS TD.160496 
 
9.9 14.0 76.1 
*RS = resistant starch  
 
Bacteria Culturing Conditions 
All bacteria were cultured at 37°C in an anaerobic chamber (Coy Laboratory Products) 
with an atmosphere composed of 2-3% H2, 20% CO2, and the balance N2. Culture media 
was composed of brain heart infusion (BHI) media supplemented with L-cysteine-HCl 
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(0.05%, w/v), resazurin (0.0001%, w/v), hemin (5 μg/mL) and Vitamin K (1 µg/mL), 
referred to herein as BHI+ and allowed to equilibrate in the anaerobic environment prior 
to use.  
 
Isolation of Bifidobacteria 
Selective isolation of Bifidobacteria was carried out by plating diluted human fecal 
samples on TOS-propionate agar (Sigma) containing lithium-mupirocin supplement 
(Sigma), followed by incubation at 37°C overnight in an anaerobic Coy chamber. Single 
colonies were randomly selected and identified by Sanger sequencing of the full-length 
16S rRNA gene. Identified bifidobacterial colonies were inoculated into fresh BHI media 
and incubated anaerobically for 24 hours, mixed with autoclaved glycerol and stored in a 
cryovial at -80°C until further use. 
 
Bacterial Growth Curves 
DL-β-Hydroxybutyric acid (Sigma 166898) was used for the in vitro bacterial growth 
studies. The βHB compound was dissolved in water and filter-sterilized to make 1M stock 
solutions. Two-fold serial dilutions of βHB were freshly prepared prior to the start of growth 
curve assays. 10 μL of each dilution or BHI+ media (for growth controls) were added in 
triplicate to wells of 96-well plates containing 40 μL of BHI+ media. Fresh cultures of 
bacteria were cultivated in BHI+ media at 37°C for 24 hours under anaerobic conditions, 
diluted to OD 0.01, then 50 μL of the diluted cultures were added to each well of 96-well 
plates except for sterile controls for which 50 μL of BHI+ media were added, making a 
total volume of 100 μL in each well. Plates were sealed with tape to minimize evaporation 
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and incubated at 37°C for 24 – 36 hours with continuous shaking, such that the growth 
controls for each isolate reached stationary phase. Growth curves were acquired by 
tracking OD at 600 nM with a microplate spectrophotometer (EON, BioTek Instruments), 
with measurements taken every 15 min. The minimal inhibitory concentration (MIC90) was 
measured as the lowest concentration of βHB that resulted in >90% growth inhibition. 
Growth parameters including carrying capacity were calculated using the Growthcurver 
R package (Sprouffske and Wagner 2016).  
 
Tree Construction 
Ribosomal sequences for each isolate were extracted from the Ribosomal Database 
Project (RDP) (Cole et al. 2014) or generated from Sanger sequencing of the full-length 
16S rRNA gene. Sequences were imported into UGENE (Okonechnikov et al. 2012) and 
aligned using MUSCLE (Edgar 2004). A maximum likelihood tree was generated using 
PhyML (Guindon et al. 2010) with 100 bootstraps and the GTR substitution model. 
 
Gnotobiotic Colonization  
B. adolescentis BD1 was inoculated into fresh BHI+ media and incubated at 37°C for 24 
hours in an anaerobic Coy chamber. A single 200 µL aliquot of the B. adolescentis culture 
(1.3 x 108 cfu/mL) or sterile BHI+ media as vehicle control was administered by oral 
gavage into each germ-free mouse within its gnotobiotic isolator. Mice were switched from 
standard chow diet to either HFD or KD on the same day as colonization, and maintained 
on their respective diets during the 12-day experiment. 
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Fecal Microbiota Transplants 
Four human donors were selected for fecal microbiota transplants, one from each study 
site. Frozen fecal samples from these human donors during BD and KD diet stages 
respectively were resuspended in 10 volumes (by weight) of BHI+ media in an anaerobic 
Coy chamber. Each diluted sample was vortexed for 1 min and left to settle for 5 min, and 
equal volumes of the clarified supernatants were pooled for gavage (one pool from four 
donor fecal samples collected during BD and a second pool containing another four 
samples collected from the same donors during KD). The KD microbiota pool was split 
into two volumes, and a third pool was prepared by spiking in fresh culture of B. 
adolescentis to one volume of the KD pool. A single 200 µL aliquot of each pooled sample 
was administered by oral gavage into each germ-free mouse within its gnotobiotic 
isolator. All mice were maintained on standard autoclaved chow diet over the 12-day 
experiment. 
 
DNA Extraction  
Human stool samples were homogenized with bead beating for 10 min on a vortex fitted 
with tube holder (MoBio, 13000-V1), using beads of mixed size and material (Lysing 
Matrix E 2mL Tube, MP Biomedicals) and the lysis solution provided in the PowerSoil 
bacterial DNA extraction kit (MoBio), and DNA was subsequently purified according to 
the manufacturer’s instructions. 
 
Mouse ileal and fecal samples were homogenized with bead beating for 5 min (Mini-
Beadbeater-96, BioSpec) using the ZR BashingBead lysis matrix containing 0.1 and 0.5 
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mm beads (ZR-96 BashingBead Lysis Rack, Zymo Research) and the lysis solution 
provided in the ZymoBIOMICS 96 MagBead DNA Kit (Zymo Research). The samples 
were then centrifuged for 5 min at 3,000 g and the supernatant was transferred to 1mL 
deep-well plates. The DNA was then purified using the ZymoBIOMICS 96 MagBead DNA 
Kit (Zymo Research) according to manufacturer’s instructions.  
 
qPCR Assessment of Bacterial Loads 
DNA was extracted as described above. Quantification against a standard curve of 
purified genomic DNA from Escherichia coli was performed by quantitative PCR of the V6 
region using BioRad iTaq Universal Probes Supermix in triplicate 10 µL reactions using 
200 nM of the following oligonucleotides:  5’-TGGAGCATGTGGTTTAATTCGA-3’, 5’-
TGCGGGACTTAACCCAACA-3’, 5’-[Cy5]CACGAGCTGACGACARCCATGCA[BHQ3] -
3’. Reactions were performed on a Bio-Rad CFX384 real-time thermocycler with the 
following cycle parameters: 95°C for 5 min followed by 40 cycles of 95°C for 5 sec, 60°C 
for 15 sec. 
 
16S rRNA Sequencing and Analysis 
DNA was isolated from human and mouse samples as described above. For human 
samples, 16S rRNA gene PCR was carried out using GoLay-barcoded 515F/806R 
primers (Caporaso et al. 2012) targeting the V4 region of the 16S rRNA gene according 
to the methods of the Earth Microbiome Project (earthmicrobiome.org). Amplicons were 
quantified with PicoGreen (Quant-It dsDNA, Life Technologies) and pooled at equimolar 
concentrations. For mouse samples, 16S rRNA gene PCR was carried out as per 
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reference protocol and primers (Gohl et al. 2016). Amplicons were pooled and normalized 
using the SequalPrep Normalization Plate Kit (Invitrogen). For both mouse and human 
samples, aliquots of the pools were then column (MinElute PCR Purification Kit, Qiagen) 
and gel purified (QIAquick Gel Extraction Kit, Qiagen). Libraries were then quantified and 
sequenced with a 600 cycle MiSeq Reagent Kit (250x250; Illumina) with ~15% PhiX. 
 
Sequencing reads were demultiplexed using QIIME before denoising and processing with 
DADA2 (Callahan et al. 2016). Taxonomy was assigned using the DADA2 implementation 
of the RDP classifier (Wang et al. 2007) using the DADA2 formatted training sets for 
SILVA123 (benjjneb.github.io/dada2/assign.html). A phylogenetic tree was constructed 
using FastTree (Price, Dehal, and Arkin 2010) with midpoint rooting. Sequence variants 
were filtered such that they were present in more than one sample with at least a total of 
10 reads. The PhILR Euclidean distance was calculated by first carrying out the 
phylogenetic isometric log ratio transformation (philr, PhILR (Silverman et al. 2017)) 
followed by calculating the Euclidean distance (vegdist, Vegan  (Dixon 2003)). Principal 
coordinates analysis was carried out using the pcoa function of APE (Paradis, Claude, 
and Strimmer 2004). ADONIS calculations were carried out (adonis, Vegan) with 999 
replications on each distance metric. The Wald test in DESeq2 package (Love, Huber, 
and Anders 2014) was used to analyze differential abundances on count data, using 
features that represented at least 0.05% of total sequencing reads. Centered log2-ratio 
(CLR) normalized abundances were calculated as Aclr=[log2(A1/ga), log2(A2/ga),… 
log2(An/ga),], where A is a vector of read counts with a prior of 0.5 added and ga is the 
geometric mean of all values of A. Time-course analysis of the ketone ester experiment 
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was carried out using linear mixed effects models (lmerTest, (Kuznetsova, Brockhoff, and 
Christensen 2017)) with mouse as a random effect to account for repeated sampling 
across time. Corrections for multiple hypothesis testing to false discovery rate (FDR) 
using the Benjamin-Hochberg method (Benjamini and Hochberg 1995) were performed 
where applicable.  
 
Metagenomic Shotgun Sequencing and Analysis  
Fecal DNA from human donors was isolated as described above. Whole-genome shotgun 
libraries were prepared using the Nextera XT DNA Library Prep Kit (Illumina). Paired ends 
of the libraries were sequenced on the Illumina HiSeq 2500 (Rapid Run mode) or 
NovaSeq 6000 platform. Raw Illumina reads underwent quality trimming and adaptor 
removal using Trimmomatic (Bolger, Lohse, and Usadel 2014) and host read removal by 
mapping to the human genome (GRCh38) with Bowtie2 (Langmead and Salzberg 2012). 
Taxonomic profiling and annotation was performed using MetaPhlAn2 (Segata et al. 
2012). 
 
Lamina Propria Lymphocyte Isolation 
Lamina propria lymphocytes (LPLs) were isolated with slight modifications of previously 
described techniques (Atarashi et al. 2011; Round et al. 2011; Kubinak et al. 2015). In 
brief, small intestinal (SI) and colonic tissues were splayed longitudinally with mucus 
removed by scraping then stored in complete RPMI (10% fetal bovine serum, 100 units 
per mL penicillin and streptomycin, β-mercaptoethanol, glutamate, sodium pyruvate, 
HEPES and non-essential amino acids). Supernatants were discarded after filtering 
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through a 100 μM filter, and remaining tissue incubated in 1X HBSS (without Ca2+and 
Mg2+) containing 5 mM EDTA (Promega) and 1 mM DL-Dithiothreitol (DTT) (Bioplus 
chemicals) for 45 min at 37°C on a shaker. Supernatants were filtered through a 100μM 
filter and discarded, and remaining tissue was incubated for 45 min (colon) or 35 min (SI) 
at 37°C on a shaker in a solution containing 1X HBSS containing 5% (v/v) fetal bovine 
serum (GIBCO heat inactivated), 1 U/mL Dispase (Sigma), 0.5 mg/mL Collagenase VIII 
(Sigma), and 20 μg/mL DNaseI (Sigma). The supernatant was filtered over a 40 µm cell 
strainer into cold sterile 1X PBS. Cells were subjected to a Percoll (VWR) gradient 
(40%/80% [v/v] gradient) and spun at 2000 RPM for 20 min with no brake and no 
acceleration. Cells at the interface were collected, washed with PBS, and prepared for 
flow cytometry analysis.  
 
Adipose Lymphocyte Isolation 
Epididymal fat pads were dissected from the same side of mice following euthanasia and 
temporarily stored in 3 mL of cold Ham’s F-10 medium prior to digestion. The tissues were 
then finely minced with scissors and digested in 3 mL of 2X digestion buffer (2 mg/mL at 
250U/mg Collagenase type I, Worthington, and 30 mg/mL bovine serum albumin in Ham’s 
F-10 medium) for 30 min at 37°C on a shaker, vortexing every 15 min. Cells were spun 
down at 1600 RPM for 7 min, resuspended in 10 mL of cold sterile 1X PBS, and filtered 
through a 40 µm cell strainer. Cells were spun down again, resuspended in PBS and 
prepared for flow cytometry analysis. 
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Flow Cytometry  
LPLs were isolated from the colonic and SI lamina propria as described above. Fat 
lymphocytes were isolated as described above. For intracellular staining, cells were first 
stimulated with ionomycin (1000 ng/mL), PMA (50 ng/mL), and Golgi Plug (1 μL/sample) 
(BD Bioscience) overnight at 37°C. Stimulated cells were stained with LIVE/DEAD Fixable 
Aqua Dead Cell Stain Kit (Thermo Fisher) according to the manufacturer’s instructions. 
Cells were surface stained with anti-CD3 (17A2, Invitrogen), anti-CD4 (GK1.5, 
Biolegend), washed, and then fixed/permeabilized in 100 μl Perm/Fix buffer (BD 
Bioscience). Cells were washed twice in Perm/Wash buffer (BD Bioscience) and then 
stained for intracellular cytokines: anti-Rorγt (B2D, Invitrogen), anti-IFNγ (XMG1.2, 
Millipore), anti-IL17a (ebio17B7, Invitrogen), anti-Foxp3 (150D, Biolegend). Cells were 
washed in Perm/Wash buffer twice and then re-suspended in staining buffer for flow 
cytometry analysis. Gating cell populations was done using isotype and single stain 
controls. These data were collected with a BD LSR Fortessa and analyzed with FlowJo 
software. 
 
β-hydroxybutyrate (βHB) Measurements 
Blood was obtained from mice by cardiac puncture immediately following euthanasia in 
the day between 9am till noon. Blood was collected into collection tubes coated with K2-
EDTA (Terumo T-MQK) or with serum separator (BD Microtainer 365978), centrifuged at 
13,000 RPM for 10 min at 4°C to separate the plasma or serum, and frozen at −20°C until 
use. βHB levels were quantified using the StanBio LiquiColor Beta-Hydroxybutyrate 
colorimetric test (StanBio) according to the manufacturer’s instructions. Baseline 
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absorbance of the sample-enzyme mixture prior to adding catalyst were subtracted from 
the final absorbance values in order to account for any sample hemolysis, with 2-3 
replicates run per sample. 
 
Ketone Ester Synthesis 
The synthesis method for the hexanoyl hexyl β-hydroxybutyrate (C6x2-βHB) ester was 
developed by Scott Ulrich of Ithaca College (Ithaca, New York, USA), and the ester was 
then custom ordered in bulk from AK Scientific (Union City, CA). The βHB moiety of the 
ester is chiral, and the compound was synthesized as an enantiomeric mixture. Briefly, 
hexyl β-hydroxybutyrate was prepared by suspending sodium β-hydroxybutyrate in dry 
dimethylformamide and reacting with 1-bromohexane, followed by hexyl acyl chloride. 
The identity of the final product was confirmed by 1H NMR and gas chromatograph mass 
spectrometry (GC/MS), with 97.5% purity on GC. 
 
NMR Global Metabolomics 
NMR spectroscopy was performed at 298K on a Bruker Avance III 600-MHz spectrometer 
configured with a 5 mm inverse cryogenic probe (Bruker Biospin, Germany) as previously 
described (Cai et al. 2017). 50 mg of fresh human feces were extracted with 1 mL of 
phosphate buffer (K2HPO4/NaH2PO4, 0.1 M, pH 7.4, 50% v/v D2O) containing 0.005% 
sodium 3-(trimethylsilyl) [2,2,3,3-2H4] propionate (TSP-d4) as a chemical shift reference 
(δ 0.00). Samples were freeze-thawed three times with liquid nitrogen and water bath for 
thorough extraction, then homogenized (6500 rpm, 1 cycle, 60s) and centrifuged (11 
180g, 4 °C, 10 min). The supernatants were transferred to a new 2 mL tube. Additional 
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600 μL of PBS was added to the pellets, followed by the same extraction procedure 
described above. Combined fecal extracts were centrifuged (11,180g, 4 °C, 10 min), 600 
μL supernatants were transferred to a 5 mm NMR tube (Norell, Morganton, NC) for NMR 
spectroscopy analysis.  A standard one-dimensional NOESY pulse sequence noesypr1d 
(recycle delay-90°-t1-90°-tm-90°-acquisition) is used with a 90 pulse length of 
approximately 10s (-9.6 dbW) and 64 transients are recorded into 32k data points with a 
spectral width of 9.6 KHz. 
 
NMR Spectra are processed as previously described (Cai et al. 2017). First, all spectra 
quality was improved with topspin 3.0 (Bruker Biospin, Germany) for phase and baseline 
correction and chemical shift calibration. Then AMIX software (version: 3.9.14, Brucker 
Biospin, Germany) was used for bucketing (bucket width 0.004 ppm), interference signal 
removing (water and polyethylene glycol), and scaling (total intensity). The following 
multivariate data analysis was performed with SIMCA 13 (Umetrics, Sweden). Orthogonal 
projection to latent structure-discriminant analysis (OPLS-DA) was performed with UV 
scaling, and the model was validated with a 7-fold cross validation method. R2X and Q2 
values generated from the method represent the predictive power and validity of the 
models, respectively. 
 
Targeted Bile Acid Quantitation by UPLC-MS/MS 
Bile acids quantitation in mouse cecal content, serum and human feces was performed 
with an ACQUITY UPLC using a BEH C8 column (1,7 µm, 100 mm x 2.1 mm) coupled 
with a Xevo TQ-S mass spectrometer equipped with an electrospray ionization (ESI) 
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source operating in negative mode (All Waters, Milford, MA) as previously described 
(Sarafian et al. 2015). Selected ion monitoring (SIR) for non-conjugated bile acid and 
multiple reaction monitoring (MRM) for conjugated bile acid were used. 50 mg of cecal 
content/feces was pre-weighed, mixed with 1 mL of pre-cooled methanol containing 0.5 
μM stable-isotope-labeled bile acids (internal standards) and 1.0 mm diameter 
zirconia/silica beads (BioSpec, Bartlesville, OK), followed by thorough homogenization 
and centrifugation. Supernatant was transferred to an autosampler vial for analysis. 100 
µL of serum was extracted by adding 200 µL pre-cooled methanol containing 0.5 μM 
internal standard bile acids. Following centrifugation, the supernatant of the extract was 
transferred to an autosampler vial for quantitation. Calibration curves of individual bile 
acids were drafted with bile acid standards for quantitation of the biological abundance of 
bile acids.  
 
RNA Extraction and qPCR Analysis for Gene Expression 
Total RNA was isolated from colonic tissues using the Direct-zol-96 MagBead kit (Zymo 
Research) as per the manufacturer’s instructions. For qPCR analysis, cDNA was 
synthesized using iScript Reverse Transcription Supermix (Bio-Rad), and qPCR was 
performed using a commercially available TaqMan Gene Expression Assay for Muc2 
(Assay ID: Mm01276694_g1) with iTaq Universal Probes Supermix (Bio-Rad) on a Bio-
Rad CFX384 real-time thermocycler. Samples were run in triplicates and normalized to 
the B2m housekeeping gene (Taqman Gene Expression Assay ID: Mm00437762_m1). 
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Intestinal Tissue Collection, Fixation and Processing 
Sections of the distal colon, closest to the rectum and containing a fecal pellet, were 
collected from mice following euthanasia and placed in cassettes. Tissues were fixed in 
methacarn solution and processed as previously described (Johansson and Hansson 
2012; Earle et al. 2015). Colon samples within cassettes were then submerged in melted 
paraffin at 68°C for 1 hr, removed, and kept at room temperature until sectioning. Paraffin 
blocks were cut into 4-μm-thick sections and deparaffinized for FISH staining. 
 
Fluorescence In Situ Hybridization (FISH) Preparation 
FISH was performed as previously described (Johansson and Hansson 2012; Earle et al. 
2015). Briefly, deparaffinized sections were incubated with the universal bacterial 
EUB338 probe (Amann et al. 1990) diluted to 10ng/μl in hybridization buffer (0.9 M NaCl, 
20 mM Tris-HCl [pH 7.4], 0.01% sodium dodecyl sulfate, 10% formamide) at 50°C for 20 
min in the dark and washed three times in PBS. Samples were then incubated with 
10μg/mL DAPI (EMD Millipore) and 40μg/mL FITC-UEA1 (Sigma) in the dark for 1 hr at 
4°C, washed three times in PBS, allowed to dry, and mounted in Vectashield mounting 
medium (Vector Labs). 
 
Imaging and Quantitation of Mucus Layer in Colon Sections 
Images were acquired on a Zeiss LSM 880 or Leica SP5 confocal microscope. Samples 
were imaged with a 63x oil-immersion objective. For quantification of mucus thickness, 
images were acquired with a frame size of 1912 X 1912 and 16-bit depth on the Zeiss 
LSM 880 microscope, with tile scans acquired using a mechanical stage and overlapping 
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images (3 x 5) stitched using the ZEN Imaging Software (black edition). Mucus thickness 
was then quantified using the analysis platform BacSpace (Earle et al. 2015). 
 
Datasets Generated and Deposited 
All sequencing datasets generated in the current study are deposited in the NCBI 
Sequence Read Archive under BioProject PRJNA529487. 
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